Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 26 June 2015, 13:29 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch New Fine Granule Formulation of Tachyarrhythmia Treatment Tambocor Suitable for Pediatric Patients in Japan

TOKYO, June 26, 2015 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it will launch Tambocor Fine Granules 10%, a new formulation of anti-arrhythmic agent Tambocor (flecainide acetate), on June 29 in Japan. Eisai received marketing and manufacturing approval for this formulation on February 16, 2015, and the product was added to Japan's National Health Insurance drug price list on June 19 of the same year.

This product is a fine granule formulation that can be adjusted to account for age and body surface area for administration to pediatric patients, and can be administered to patients who have difficulty taking tablets. In addition, Eisai has made special efforts, such as reducing the bitterness, to make Tambocor Fine Granules easy to administer.

Tambocor suppresses tachyarrythmia by blocking cardiac sodium channels and slowing down cardiac conduction. Approved and launched as Tambocor Tablets in Japan in 1991, the drug was originally indicated for the treatment of tachyarrythmia in adults, and was approved for the treatment of tachyarrythmia (paroxysmal atrial fibrillation/flutter, paroxysmal superventricular, ventricular) in pediatric patients in May 2010. Furthermore, Tambocor is the only sodium channel blocking agent in Japan to be approved for the treatment of tachyarrythmia in pediatric patients.

Pediatric arrhythmia not only causes heart palpitations, dizziness, shortness of breath and other symptoms that impact the daily lives of patients, it is also said to be one of the most common causes of sudden death among children. Regarding pediatric arrhythmia, Eisai has received approval of additional indications for pediatric patients for Tambocor Tablets in May 2010, and for the calcium channel blocker Vasolan Tablets 40 mg and Vasolan for intravenous injection 5 mg in May 2011. By providing the easy to measure and administer Tambocor Fine Granules 10% in addition to Tambocor Tablets, Eisai will continue to make further contributions to address their needs of patients with tachyarrhythmia.

Notes to editors:

1. About Tambocor Fine Granules 10%
1) Product Name
Tambocor Fine Granules 10%
2) Generic Name
Flecainide acetate
3) Indications, Dosage & Administration
- Indications
The following conditions where other antiarrhythmic drugs cannot be used or are ineffective:
Adults: Tachyarrhythmia(paroxysmal atrial fibrillation/flutter, ventricular)
Pediatric patients: Tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal superventricular, ventricular)
- Dosage & Administration
Adults:
- Tachyarrhythmia (paroxysmal atrial fibrillation/flutter)
The usual initial adult dose is 100 mg (1 g as fine granule) of flecainide acetate daily. If the effect is insufficient, the dose may be increased up to 200 mg (2 g as fine granule) daily, which should be administered in two divided doses. The dose may be reduced depending on the patient's age and symptoms.
- Tachyarrhythmia (ventricular)
The usual initial adult dose is 100 mg (1 g as fine granule) of flecainide acetate daily. If the effect is insufficient, the dose may be increased up to 200 mg (2 g as fine granule) daily, which should be administered in two divided doses. The dose may be adjusted depending on the patient's age and symptoms.
Pediatric patients:
- Tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal superventricular, ventricular)
The usual oral dosage for infants over 6 months old or over, toddlers, and children is 50-100 mg/m2 (body surface area) [0.5-1 g/m2 (body surface area) as fine granule] of flecainide acetate daily in two to three divided doses. The dose may be adjusted depending on the patient's age and symptoms. The maximum dose is 200 mg/m2 per day [2 g/m2 (body surface are) as fine granule] daily.
The usual oral dosage for infants under the age of 6 months is 50 mg/m2 (body surface area) [0.5 g/m2 (body surface area) as fine granule] of flecainide acetate daily in two to three divided doses. The dose may be adjusted depending on the patient's age and symptoms. The maximum dose is 200 mg/m2 per day [2 g/m2 (body surface area) as fine granule] daily.
4) Price
Tambocor Fine Granules 10%: 202.20 yen per 1 g containing 10% (package price: 10,110 yen)
5) Packaging
Bottles of 50 g


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120



Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Nov 28, 2024 15:26 HKT/SGT
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Nov 26, 2024 14:50 HKT/SGT
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: